Author

Liberty François‐Moutal

University of ArizonaORCID 0000-0003-1277-660XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:rat· 3 Research Focus:drug response / drug discovery· 2 Research Focus:cell type annotation· 1 Organism:human· 1 Assay:protein structure· 1 Assay:proteomics· 1

Frequent Co-Authors

Aubin MoutaliD· 4 shared Rajesh KhannaiD· 3 shared Shizhen LuoiD· 3 shared Aida Calderón‐RiveraiD· 2 shared Cheng Wu TangiD· 2 shared Dongzhi RaniD· 2 shared Harrison J. StrattoniD· 2 shared Jérôme HonnoratiD· 2 shared

Activity by Year

2019-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersNeuroscience

Aubin MoutalORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

NeuroscienceAdvanced SciencePeer-reviewedFeb 17, 2026

Pathogenic Role of FGFR3 Autoantibodies in Small Fiber Neuropathy

Lyuba Y. Salih, Nicolas Dumaire, Clémence Gieré…·Aubin Moutal

This study shows FGFR3 autoantibodies cause small fiber neuropathy by directly affecting DRG neurons, suggesting they are pathogenic and therapeutic targets.

2 citationstop 3%

humanproteomics

𝕏 PostBluesky

NeuroscienceNature CommunicationsPeer-reviewedAug 7, 2025

Mechanism, and treatment of anti-CV2/CRMP5 autoimmune pain

Laurent Martin, Harrison J. Stratton, Lyuba Y. Salih…·Aubin Moutal

This study investigates how anti-CV2/CRMP5 autoantibodies cause pain in paraneoplastic neurological syndromes and identifies potential treatments.

16 citationstop 1%

ratexperimental assay

𝕏 PostBluesky

NeuroscienceProceedings of the National Academy of SciencesPeer-reviewedJul 27, 2023

Identification and targeting of a unique NaV1.7 domain driving chronic pain

Kimberly Gómez, Harrison J. Stratton, Paz Duran…·Rajesh Khanna

The paper identifies a unique NaV1.7 domain that can be targeted to produce analgesia by disrupting its interaction with CRMP2.

52 citationstop 1%

ratprotein structure

𝕏 PostBluesky

NeurosciencePainPeer-reviewedFeb 5, 2019

Targeting the CaV - interaction yields a selective antagonist of the N-type CaV2.2 channel with broad antinociceptive efficacy

Rajesh Khanna, Jie Yu, Xiao-Fang Yang…·May Khanna

The paper identifies a novel CaV2.2 channel antagonist with broad antinociceptive effects and reduced side effects in pain models.

43 citations

ratexperimental assay

𝕏 PostBluesky